Results 161 to 170 of about 57,164 (280)

Structure−Activity Relationships of New 1‐Aryl‐1H‐Indole Derivatives as SARS‐CoV‐2 Nsp13 Inhibitors

ChemMedChem, Volume 20, Issue 14, July 18, 2025.
SARS‐CoV‐2 nsp13 is a promising target to develop effective antivirals. Pursuing the studies, new indolyl derivatives to deepen SARs are designed. The newly synthesized N‐aryl indoles are active vs both nsp13‐associated activities. They exert antiviral activity vs SARS‐CoV‐2 infected cells with no cytotoxicity.
Valentina Noemi Madia, Roberta Emmolo, Elisa Patacchini, Donatella Amatore, Stefania Maloccu, Davide Ialongo, Aurora Albano, Giuseppe Ruggieri, Emanuele Cara, Laura Zarbo, Antonella Messore, Riccardo De Santis, Alessandra Amoroso, Florigio Lista, Francesca Esposito, Enzo Tramontano, Angela Corona, Roberto Di Santo, Roberta Costi   +18 more
wiley   +1 more source

Remdesivir Use in the Setting of Severe Renal Impairment: A Theoretical Concern or Real Risk? [PDF]

, 2020
Natasha N. Pettit, Jennifer Pisano, Cynthia T. Nguyen, Alison Lew, Aniruddha Hazra, Renslow Sherer, Kathleen M. Mullane   +6 more
openalex   +1 more source

Safety and effectiveness of remdesivir for the treatment of COVID-19 patients with end-stage renal disease: A retrospective cohort study

Journal of Microbiology, Immunology and Infection
Background: Remdesivir has been used to treat severe coronavirus 2019 (COVID-19); however, its safety and effectiveness in patients remain unclear. This study aimed to investigate the safety and effectiveness of remdesivir in patients with COVID-19 with ...
Yan-Bo Huang, Chip-Jin Ng, Cheng-Hsun Chiu, Chung-Hsien Chaou, Shi-Ying Gao, Shou-Yen Chen   +5 more
doaj  

Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU [PDF]

, 2020
Zeno Pasquini, Roberto Montalti, Chiara Temperoni, Benedetta Canovari, Mauro Mancini, Michele Tempesta, D Pimpini, Nicoletta Zallocco, Francesco Barchiesi   +8 more
openalex   +1 more source

Remdesivir as a possible therapeutic option for the COVID-19 [PDF]

, 2020
Al-Homoud, Ali H., Al-Tawfiq, Jaffar A., Memish, Ziad A.   +2 more
core   +1 more source

A mechanism‐based pharmacokinetic model of remdesivir leveraging interspecies scaling to simulate COVID‐19 treatment in humans [PDF]

, 2020
Patrick O. Hanafin, Brian Jermain, Anthony J. Hickey, Alexander V. Kabanov, Angela D. M. Kashuba, Timothy P. Sheahan, Gauri G. Rao   +6 more
openalex   +1 more source

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

The Lancet, 2020
Ye-ming Wang, Dingyu Zhang, G. Du, R. Du, Jianping Zhao, Yang Jin, Shouzhi Fu, Ling Gao, Zhenshun Cheng, Q. Lu, Y. Hu, G. Luo, Ke Wang, Yang Lu, Huadong Li, Shuzhen Wang, Shunan Ruan, Chengqing Yang, Chunlin Mei, Yi Wang, Dan Ding, Feng Wu, Xin Tang, X. Ye, Yingchun Ye, Bing Liu, Jie Yang, Wen Yin, Aili Wang, Guohui Fan, F. Zhou, Zhibo Liu, Xiaoying Gu, Jiuyang Xu, L. Shang, Yi Zhang, Lianjun Cao, Tingting Guo, Y. Wan, H. Qin, Yushen Jiang, T. Jaki, F. Hayden, P. Horby, B. Cao, Chen Wang   +45 more
semanticscholar   +1 more source

Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir

Viruses, 2019
Remdesivir (GS-5734) is a 1′-cyano-substituted adenosine nucleotide analogue prodrug that shows broad-spectrum antiviral activity against several RNA viruses. This compound is currently under clinical development for the treatment of Ebola virus disease (
E. Tchesnokov, Joy Y. Feng, D. Porter, M. Götte   +3 more
semanticscholar   +1 more source

Trends in the development of remdesivir based inventions against COVID-19 and other disorders: A patent review

Journal of Infection and Public Health, 2021
The development of remdesivir has been a breakthrough for COVID-19 treatment. It has been approved in about 50 countries, including Saudi Arabia, since 2020. The generic structure of remdesivir was first disclosed in 2009.
Mohd. Imran, Ahmed Subeh Alshrari, Syed Mohammed Basheeruddin Asdaq, Abida   +3 more
doaj  

Management of Vulnerable Patients Hospitalized for COVID-19 With Remdesivir: A Retrospective Comparative Effectiveness Study of Mortality in US Hospitals. [PDF]

BACKGROUND: Coronavirus disease 2019 (COVID-19) remains a major public health concern, with continued resurgences of cases and substantial risk of mortality for hospitalized patients.
Ahuja, Neera, Amin, Alpesh, Berry, Mark, Casciano, Roman, Chandak, Aastha, Doi, Yohei, Kolditz, Martin, Loubet, Paul, Mozaffari, Essy, Müller, Veronika, Sax, Paul   +10 more
core   +1 more source